Published in J Acquir Immune Defic Syndr on December 01, 1999
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
Psychiatric and neurophysiological predictors of obesity in HIV/AIDS. Psychophysiology (2008) 0.88
HIV Wasting Syndrome in a Nigerian Failing Antiretroviral Therapy: A Case Report and Review of the Literature. Case Rep Med (2010) 0.75
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 5.94
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Race/ethnicity, social class and their relation to physical inactivity during leisure time: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Prev Med (2000) 4.73
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
"Sick of Smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust (1990) 4.11
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Television watching, energy intake, and obesity in US children: results from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med (2001) 3.63
Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology (1993) 3.53
Water disinfection in the wilderness--a simple, effective method of iodination. West J Med (1975) 3.52
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int (2006) 3.03
A method for measurement of antibiotics in human interstitial fluid. J Infect Dis (1972) 2.99
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Acculturation and leisure-time physical inactivity in Mexican American adults: results from NHANES III, 1988-1994. Am J Public Health (2001) 2.88
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med (1990) 2.56
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol (1990) 2.50
Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J Acquir Immune Defic Syndr (1989) 2.48
Relation between sexual practices and T-cell subsets in homosexually active men. Lancet (1983) 2.46
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Potential factors affecting adherence with HIV therapy. AIDS (1997) 2.44
A modified assay of neutrophil function: use of lysostaphin to differentiate defective phagocytosis from impaired intracellular killing. J Lab Clin Med (1971) 2.40
Accelerated course of human immunodeficiency virus infection in gay men who conceal their homosexual identity. Psychosom Med (1996) 2.40
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis (1995) 2.25
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25
A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother (1997) 2.22
Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med (1988) 2.18
Some salient features of Staphylococcus aureus endocarditis. Am J Med (1973) 2.17
Detection and characterization of broad-host-range plasmids in environmental bacteria by PCR. Appl Environ Microbiol (1996) 2.14
Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr (2000) 2.13
Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol (1999) 2.11
In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin. Appl Microbiol (1969) 2.09
Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry (1993) 2.07
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology (2007) 2.05
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis (1994) 2.04
Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology (2009) 2.00
Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol (2000) 1.95
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet (1991) 1.89
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet (2009) 1.87
A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol (2004) 1.87
Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS (2001) 1.84
Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) (2005) 1.82
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol (1987) 1.80
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res (1999) 1.77
Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol (1998) 1.76
Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med (1986) 1.67
Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr (1993) 1.67
Comparison of CD4 cell count by a simple enzyme-linked immunosorbent assay using the TRAx CD4 test kit and by flow cytometry and hematology. Clin Diagn Lab Immunol (1995) 1.66
Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1992) 1.66
Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr (1992) 1.65
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother (2005) 1.63
Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.61
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol (1993) 1.59
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Disclosure of HIV antibody status: behavioral and mental health correlates. AIDS Educ Prev (1989) 1.57
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis (1994) 1.55
Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol (2001) 1.55
Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis (1997) 1.54
Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr (1999) 1.53
Effect of smoking on the clinical progression of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.53
Elevated physical health risk among gay men who conceal their homosexual identity. Health Psychol (1996) 1.52
Purulent pneumococcal pericarditis. A continuing problem in the antibiotic era. Am J Med (1973) 1.51
Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis (1999) 1.51